Laura Sepp-Lorenzino - 01 Jun 2026 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Reporting relationship: Director
Issuer ticker: TSHA
Reported as of: 01 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2026, 16:30:15 UTC
Prior SEC filing: 30 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Kamran Alam, Attorney-in-Fact

Key filing fact

Laura Sepp-Lorenzino filed Form 4 for Taysha Gene Therapies, Inc. (TSHA) on 02 Jun 2026.

Key facts

This page summarizes Laura Sepp-Lorenzino's Form 4 filing for Taysha Gene Therapies, Inc. (TSHA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Jun 2026, 16:30.

Change

Previous filing in this sequence was filed on 30 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001777421 Primary reporting owner

Sepp-Lorenzino Laura

Relationship: Director
Address: C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS
Signature: /s/ Kamran Alam, Attorney-in-Fact
Signature date: 02 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TSHA transaction

Common Stock

Award

Transaction value
Shares: +21,335
Change %: +20%
Price: $0.000000^*
Shares after: 127,178
Date: 01 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TSHA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +42,671
Change %
Price: $0.000000^*
Shares after: 42,671
Date: 01 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 42,671
Exercise price: $5.97
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.

Footnote F2

The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.